Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rubius Therapeutics Inc. RUBY

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.


Recent & Breaking News (NDAQ:RUBY)

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

GlobeNewswire 6 days ago

Rubius Therapeutics Announces Strategic Update

GlobeNewswire 12 days ago

Rubius Therapeutics to Provide Strategic Update

GlobeNewswire 13 days ago

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 9, 2022

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

GlobeNewswire July 26, 2022

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

PR Newswire July 19, 2022

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

GlobeNewswire July 14, 2022

Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

GlobeNewswire June 22, 2022

Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2022

Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 26, 2022

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

GlobeNewswire May 24, 2022

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 10, 2022

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

GlobeNewswire April 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rubius Therapeutics, Inc. - RUBY

PR Newswire April 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rubius Therapeutics, Inc. - RUBY

Newsfile April 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rubius Therapeutics, Inc. - RUBY

PR Newswire April 11, 2022

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

GlobeNewswire April 8, 2022

Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET

GlobeNewswire April 7, 2022

Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting

GlobeNewswire March 8, 2022

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

PR Newswire February 28, 2022